The global medical foods for inborn errors of metabolism market is expected to reach USD 6,717.16 million by 2030 from USD 2,477.81 million in 2022, growing at a CAGR of 13.5% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Medical Foods for Inborn Errors of Metabolism Market, By Products (Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Low Protein Food, and Others), Age Group (Infants, Weaning, Adolescent, and Adults), Diseases (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Tyrosinemia Types I and II, Urea Cycle Disorders, and Others), Forms (Powder, Liquid, Tablets, Gels, and Others), Packaging (Can, Jar, Packets, Bottle, and Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Drug Stores, Online Pharmacy, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Finland, Denmark, Sweden, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, New Zealand, Vietnam, Philippines, Taiwan, Rest of Asia-Pacific Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, Bahrain, U.A.E., Kuwait, Qatar, Egypt, Oman, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.
Overview of Global Medical Foods for Inborn Errors of Metabolism Market Dynamics
- Driver
- Increase in the incidence of IEMs
- Restraint
- High cost associated with medical food products
- Opportunity
- Preference of dietary supplements over enzyme replacement therapy
Market Players
Some of the major market players operating in the global medical foods for inborn errors of metabolism are:
- Abbott
- Nestle Health Science (A Subsidiary of Nestle)
- Ajinomoto Cambrooke, Inc. (A Subsidiary of Ajinomoto Co., Inc.)
- Mead Johnson & Company, LLC. (A Subsidiary of Reckitt Benckiser Group plc.)
- Nutricia (A Subsidiary of Danone)
- Baxter
- Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA)
- Meiji Holdings Co., Ltd.
- B. Braun SE
- Dr. Schar AG / SPA
- Kate Farms
- Hexagonnutrition Ltd.
- Primus Pharmaceuticals, Inc.
- Ener-G Foods, Inc.
- PKU Perspectives
- Piam Farmaceutici S.P.A.
- Promin Metabolics
- Orpharma Pty Ltd.
- Pristine Organics Private Limited
- Solace Nutrition
- EBM Medical
- Galen Limited
- PKU-Mdmil
- APR
TABLE OF CONTENTS
1 INTRODUCTION 60
- 1.1 OBJECTIVES OF THE STUDY 60
- 1.2 MARKET DEFINITION 60
- 1.3 OVERVIEW 60
- 1.4 CURRENCY AND PRICING 62
- 1.5 LIMITATIONS 62
- 1.6 MARKETS COVERED 62
2 MARKET SEGMENTATION 68
- 2.1 MARKETS COVERED 68
- 2.2 GEOGRAPHICAL SCOPE 69
- 2.3 YEARS CONSIDERED FOR THE STUDY 70
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 71
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 74
- 2.6 MULTIVARIATE MODELLING 75
- 2.7 PRODUCTS LIFELINE CURVE 75
- 2.8 DBMR MARKET POSITION GRID 76
- 2.9 SECONDARY SOURCES 78
- 2.10 ASSUMPTIONS 78
3 EXECUTIVE SUMMARY 79
4 PREMIUM INSIGHT 83
- 4.1 PESTEL ANALYSIS 85
- 4.2 PORTER'S FIVE FORCES MODEL 86
- 4.3 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET ANALYSIS 87
- 4.4 PATENT ANALYSIS 88
5 PIPELINE ANALYSIS 90
6 EPIDEMIOLOGY 91
7 INDUSTRY INSIGHTS 92
- 7.1 DEMOGRAPHIC TRENDS 92
- 7.2 KEY PRICING STRATEGIES 94
- 7.3 KEY PATIENT ENROLLMENT STRATEGIES 95
8 REGULATORY SCENARIO FOR MEDICAL FOOD 97
9 MARKET OVERVIEW 100
- 9.1 DRIVERS 102
- 9.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM (IEM) 102
- 9.1.2 RISING PREFERENCE FOR DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY (ERT) 103
- 9.1.3 INCREASE IN THE NUMBER OF NEW-BORN SCREENING PROCEDURES 104
- 9.1.4 INCREASING SPENDING ON MEDICAL FOOD PRODUCTS 105
- 9.2 RESTRAINTS 106
- 9.2.1 HIGH COST OF MEDICAL FOODS 106
- 9.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS 107
- 9.3 OPPORTUNITIES 108
- 9.3.1 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT INBORN ERRORS OF METABOLISM 108
- 9.3.2 INCREASING COLLABORATIONS AND PARTNERSHIPS IN THE MARKET 110
- 9.3.3 EXPANSION OF MEDICAL FOODS IN EMERGING MARKETS 110
- 9.4 CHALLENGES 111
- 9.4.1 POOR ACCESSIBILITY OF MEDICAL FOODS 111
- 9.4.2 ALTERNATIVE TREATMENT APPROACHES FOR INBORN ERRORS OF METABOLISM 112
10 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS 113
- 10.1 OVERVIEW 114
- 10.2 AMINO ACID 117
- 10.2.1 AMINO ACID MIXTURES 118
- 10.2.1.1 PHENYLADE 119
- 10.2.1.1.1 DRINK MIX 119
- 10.2.1.1.2 GMP MIX-IN 119
- 10.2.1.1.3 GMP READY 119
- 10.2.1.1.4 OTHERS 119
- 10.2.1.2 PERIFLEX 119
- 10.2.1.3 LOPHLEX 120
- 10.2.1.4 PHLEXY 120
- 10.2.1.5 COOLER 120
- 10.2.1.6 ANAMIX 120
- 10.2.1.7 LYSINE-FREE, LOW TRYPTOPHAN 120
- 10.2.1.8 GLUTARADE ESSENTIAL GA-1 120
- 10.2.1.9 GLUTARADE GA-1 AMINO ACID BLEND 120
- 10.2.1.10 GLYTACTIN WITH GMP 120
- 10.2.1.11 ESSENTIAL AMINO ACID MIX 120
- 10.2.1.12 LIQUIGEN 120
- 10.2.1.13 MSUD GEL 121
- 10.2.1.14 OTHERS 121
- 10.2.2 SINGLE AMINO ACID 121
- 10.2.2.1 L-ARGININE 121
- 10.2.2.2 L-ISOLEUCINE 121
- 10.2.2.3 L-TYROSINE 122
- 10.2.2.4 L-LEUCINE 122
- 10.2.2.5 GLYCINE 122
- 10.2.2.6 L-ASPARTIC ACID 122
- 10.2.2.7 L-CITRULLINE 122
- 10.2.2.8 OTHERS 122
- 10.3 LOW PROTEIN FOOD 122
- 10.3.1 LOW-PROTEIN BAKING MIXES AND FLOUR SUBSTITUTES, SUCH AS RICE FLOUR OR POTATO FLOUR 124
- 10.3.2 LOW-PROTEIN ENERGY BARS AND SNACKS 124
- 10.3.3 LOW-PROTEIN CEREALS AND BREAKFAST FOOD 124
- 10.3.4 LOW-PROTEIN MILK SUBSTITUTES, SUCH AS RICE MILK OR ALMOND MILK 124
- 10.3.5 LOW-PROTEIN BREAD, PASTA, AND OTHER GRAIN-BASED PRODUCTS 124
- 10.3.6 OTHERS 124
- 10.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON 124
- 10.4.1 BY FLAVOUR 125
- 10.4.1.1 VANILLA 125
- 10.4.1.2 BERRY 125
- 10.4.1.3 ORANGE 126
- 10.4.1.4 PLAIN 126
- 10.4.1.5 OTHERS 126
- 10.4.2 BY USAGE 126
- 10.4.2.1 READY TO DRINK 126
- 10.4.2.2 NEED DILUTION/PREPARATION 126
- 10.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON 127
- 10.5.1 NO CALCIUM OR VITAMIN D 128
- 10.5.2 LOW CALCIUM, NO VITAMIN D 128
- 10.5.3 OTHERS 128
- 10.6 OTHERS 128
11 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES 130
- 11.1 OVERVIEW 131
- 11.2 PHENYLKETONURIA (PKU) 134
- 11.2.1 PHENYLADE 135
- 11.2.2 PERIFLEX 135
- 11.2.3 LOPHLEX 135
- 11.2.4 OTHERS 135
- 11.3 TYROSINEMIA TYPES I AND II 135
- 11.4 MAPLE SYRUP URINE DISEASE (MSUD) 136
- 11.4.1 ANAMIX 137
- 11.4.2 COOLER 137
- 11.4.3 MSUD GEL 137
- 11.4.4 AMINO ACID BLEND 137
- 11.4.5 MAXMUM 137
- 11.4.6 OTHERS 137
- 11.5 HOMOCYSTINURIA 138
- 11.6 GLUTARIC ACIDEMIA TYPE I 138
- 11.7 UREA CYCLE DISORDERS 139
- 11.7.1 ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC) 140
- 11.7.2 CARBAMYL PHOSPHATE SYNTHETASE DEFICIENCY (CPS) 140
- 11.7.3 CITRULLINAEMIA 140
- 11.7.4 N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY (NAGS) 140
- 11.7.5 ARGINASE DEFICIENCY (AG) 141
- 11.7.6 ARGININOSUCCINIC ACIDURIA (ASA) 141
- 11.7.7 OTHERS 141
- 11.8 METHYLMALONIC ACIDEMIA 141
- 11.9 ISOVALERIC ACIDEMIA 142
- 11.10 ORGANIC ACIDURIAS 143
- 11.11 RENAL DISEASE 143
- 11.12 PROPIONIC ACIDEMIA 144
- 11.13 DISORDERS OF LEUCINE METABOLISM 145
- 11.14 OTHERS 146
12 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP 147
- 12.1 OVERVIEW 148
- 12.2 INFANTS 151
- 12.3 WEANING 151
- 12.4 ADOLESCENT 152
- 12.5 ADULTS 153
13 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS 154
- 13.1 OVERVIEW 155
- 13.2 POWDER 158
- 13.3 LIQUID 158
- 13.4 TABLETS 159
- 13.5 GELS 160
- 13.6 OTHERS 161
14 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING 162
- 14.1 OVERVIEW 163
- 14.2 CAN 166
- 14.3 PACKETS 166
- 14.4 BOTTLE 167
- 14.5 JAR 168
- 14.6 OTHERS 168
15 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL 170
- 15.1 OVERVIEW 171
- 15.2 HOSPITAL PHARMACY 174
- 15.3 RETAIL PHARMACY 174
- 15.4 DRUG STORES 175
- 15.5 ONLINE PHARMACY 176
- 15.6 OTHERS 176
16 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION 178
- 16.1 OVERVIEW 179
- 16.2 NORTH AMERICA 184
- 16.2.1 U.S. 195
- 16.2.2 CANADA 202
- 16.2.3 MEXICO 209
- 16.3 EUROPE 216
- 16.3.1 GERMANY 230
- 16.3.2 FRANCE 239
- 16.3.3 U.K. 248
- 16.3.4 ITALY 257
- 16.3.5 SPAIN 266
- 16.3.6 SWITZERLAND 276
- 16.3.7 NETHERLANDS 285
- 16.3.8 BELGIUM 294
- 16.3.9 DENMARK 303
- 16.3.10 RUSSIA 312
- 16.3.11 SWEDEN 320
- 16.3.12 TURKEY 328
- 16.3.13 POLAND 336
- 16.3.14 FINLAND 344
- 16.3.15 NORWAY 351
- 16.3.16 REST OF EUROPE 359
- 16.4 ASIA-PACIFIC 360
- 16.4.1 CHINA 375
- 16.4.2 JAPAN 385
- 16.4.3 INDIA 394
- 16.4.4 AUSTRALIA 404
- 16.4.5 SOUTH KOREA 414
- 16.4.6 THAILAND 423
- 16.4.7 SINGAPORE 433
- 16.4.8 INDONESIA 442
- 16.4.9 MALAYSIA 451
- 16.4.10 NEW ZEALAND 460
- 16.4.11 VIETNAM 468
- 16.4.12 PHILIPPINES 476
- 16.4.13 TAIWAN 486
- 16.4.14 REST OF ASIA-PACIFIC 495
- 16.5 SOUTH AMERICA 496
- 16.5.1 BRAZIL 508
- 16.5.2 ARGENTINA 515
- 16.5.3 REST OF SOUTH AMERICA 523
- 16.6 MIDDLE EAST AND AFRICA 524
- 16.6.1 SOUTH AFRICA 535
- 16.6.2 SAUDI ARABIA 542
- 16.6.3 BAHRAIN 549
- 16.6.4 UNITED ARAB EMIRATES 557
- 16.6.5 KUWAIT 564
- 16.6.6 QATAR 572
- 16.6.7 EGYPT 579
- 16.6.8 OMAN 586
- 16.6.9 REST OF MIDDLE EAST AND AFRICA 593
17 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE 594
- 17.1 COMPANY SHARE ANALYSIS: GLOBAL 594
- 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 595
- 17.3 COMPANY SHARE ANALYSIS: EUROPE 596
- 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 597
18 SWOT ANALYSIS 598
19 COMPANY PROFILE 599
- 19.1 ABBOTT 599
- 19.1.1 COMPANY SNAPSHOT 599
- 19.1.2 REVENUE ANALYSIS 599
- 19.1.3 COMPANY SHARE ANALYSIS 600
- 19.1.4 PRODUCT PORTFOLIO 600
- 19.1.5 RECENT DEVELOPMENT 601
- 19.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE) 602
- 19.2.1 COMPANY SNAPSHOT 602
- 19.2.2 COMPANY SHARE ANALYSIS 602
- 19.2.3 PRODUCT PORTFOLIO 603
- 19.2.4 RECENT DEVELOPMENT 603
- 19.3 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.) 604
- 19.3.1 COMPANY SNAPSHOT 604
- 19.3.2 COMPANY SHARE ANALYSIS 604
- 19.3.3 PRODUCT PORTFOLIO 605
- 19.3.4 RECENT DEVELOPMENTS 605
- 19.4 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.) 606
- 19.4.1 COMPANY SNAPSHOT 606
- 19.4.2 COMPANY SHARE ANALYSIS 606
- 19.4.3 PRODUCT PORTFOLIO 607
- 19.4.4 RECENT DEVELOPMENT 607
- 19.5 NUTRICIA (A SUBSIDIARY OF DANONE) 608
- 19.5.1 COMPANY SNAPSHOT 608
- 19.5.2 COMPANY SHARE ANALYSIS 608
- 19.5.3 PRODUCT PORTFOLIO 609
- 19.5.4 RECENT DEVELOPMENT 610
- 19.6 APR 611
- 19.6.1 COMPANY SNAPSHOT 611
- 19.6.2 PRODUCT PORTFOLIO 611
- 19.6.3 RECENT DEVELOPMENT 611
- 19.7 B.BRAUN SE 612
- 19.7.1 COMPANY SNAPSHOT 612
- 19.7.2 PRODUCT PORTFOLIO 612
- 19.7.3 RECENT DEVELOPMENT 612